Treatment Planning & Protocols Flashcards

A protocol specifies treatment until 'disease progression or unacceptable toxicity.' A subject's imaging shows stable disease but the subject reports significantly worsening quality of life. Should the investigator discontinue treatment?

Answer: Yes, if the deterioration meets the protocol's definition of 'unacceptable toxicity' or falls under investigator clinical judgment criteria

Significant quality of life deterioration may meet protocol-defined unacceptable toxicity criteria or fall within the investigator's discretion to discontinue in the subject's best interest.

A Phase II protocol uses a 'Simon two-stage design.' What is the purpose of the first stage in this design?

Answer: To allow early termination for futility if insufficient responses are observed in the initial cohort

The Simon two-stage design allows early stopping for futility after Stage 1 if the response rate does not meet a pre-specified threshold, conserving resources.

A protocol's concomitant medication section prohibits 'strong CYP3A4 inhibitors.' A subject requires ketoconazole for a fungal infection. The investigator should:

Answer: Consult the protocol's pharmacology rationale, explore alternative antifungals, and contact the sponsor before making a decision

Before making a decision, the investigator should explore alternative antifungals not prohibited by the protocol and consult the sponsor regarding risk-benefit.

In a protocol, 'crossover design' means subjects:

Answer: Receive multiple treatments in sequence, with each subject serving as their own control

In a crossover design, subjects receive each treatment in sequence with washout periods between them, allowing within-subject comparisons.

A protocol requires that study drug be returned and accounted for at each visit. A subject arrives with an empty bottle but reports taking all doses as prescribed. The investigator should:

Answer: Document the subject's account, perform pill count of available materials, and record any discrepancy in the drug accountability log

Drug accountability requires documentation of all discrepancies between dispensed and returned quantities, with the subject's explanation recorded.

When a protocol specifies 'individualized dose titration,' what principle distinguishes this from fixed-dose protocols?

Answer: Doses are adjusted based on individual subject response, tolerability, or biomarker levels within protocol-defined limits

Individualized dose titration adjusts doses for each subject based on defined criteria such as response or toxicity, within protocol-specified minimum and maximum limits.

A Phase III protocol requires 'overall survival' (OS) as the primary endpoint. A Data Safety Monitoring Board (DSMB) reviews interim data and recommends early trial termination for efficacy. The investigator's role at this point is to:

Answer: Follow the sponsor's instructions based on the DSMB recommendation, including stopping enrollment and notifying subjects

When a DSMB recommends early termination for efficacy, the investigator follows sponsor directives, which include stopping enrollment and notifying subjects and the IRB per protocol procedures.